When was Likarda founded?

Likarda was founded in 2012 and raised its 1st funding round 5 years after it was founded.

Where is Likarda located?

Likarda is headquartered in Kansas City, United States.

How many employees does Likarda have?

As of Mar 31, 2026, the latest employee count at Likarda is 14.

Is Likarda a funded company?

Likarda is a funded company, having raised a total of $4M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 28, 2017.

When was the latest funding round of Likarda?

Likarda's latest funding was a $***** Grant (prize money) round on Sep 07, 2021, with participation from 1 investor.

Where does Likarda rank among its competitors?

Likarda ranks 1st amongst 8 active competitors, of which 3 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Gel Coat Biomaterials, which secured $1.33M in Feb, 2024.

Who are the top competitors of Likarda?

Likarda's top competitors include Biogelx, Gel Coat Biomaterials and Sumatrix Biotech. Among them, Gel Coat Biomaterials secured the most recent funding round in February, 2024.

Likarda - 2026 Company Profile, Team, Funding & Competitors

Company Details

Likarda is creating 3D cell cultures/miniaturized organs from their proprietary cell culture systems which will have potential applications in drug discovery, development, cell-based transplantation, and regenerative medicine. The company offers integrated early-stage discovery research along with consultative and analytical services. The company has created Kanslet, a reaggregated islet capable of producing insulin (from a donor pancreas) which can be transplanted into dogs and cats for treating diabetes. Kanslets can also be used for secondary drug testing and multiple studies have been published already in support of the technology.

Website: likarda.com
Social
Email ID: *****@likarda.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Kansas City, United States

Stage

Series A

Total Funding

$4M in 2 rounds

Latest Funding Round

Grant (prize money), Sep 07, 2021, $*****

Investors

Werth Ventures & 1 more

Ranked

1^st among 8 active competitors

Employee Count

14 as on Mar 31, 2026

Similar Companies

Biogelx & 6 more

View Likarda's full profile

Likarda is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Likarda, Llc CIN: 455467495 , United States, Active	Dec 31, 1999	-	7 (As on Dec 31, 2024)	-

Likarda has raised a total funding of $4M over 2 rounds. Its first funding round was on Aug 28, 2017. Its latest funding round was a Grant (prize money) round on Sep 07, 2021 for $*****. 1 investor participated in its latest round. Likarda has 2 institutional investors.

Here is the list of recent funding rounds of Likarda:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 07, 2021	1151471	Grant (prize money)	7571997	5784738	6701574	7015759
Aug 28, 2017	3431110	Series A	2609582	8742696	6245740	6291799

Access funding benchmarks and valuations. Sign up today!

View details of Likarda's funding rounds and investors

The founders of Likarda are Karthik Ramachandran and Lisa Stehno-Bittel.

Here are the details of Likarda's key team members:

Karthik Ramachandran: Chief Business Officer & Founder of Likarda.
Lisa Stehno-Bittel: President and Co-Founder of Likarda.

View details of Likarda's Founder profiles and Board Members

Likarda's employee count trend

Likarda has 14 employees as of Mar 26. Here is Likarda's employee count trend over the years:

Uncover Likarda's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Likarda include Biogelx, Gel Coat Biomaterials and Sumatrix Biotech. Here is the list of Top 10 competitors of Likarda, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Likarda 2012, Kansas City (United States), Series A	Developer of 3D cell cultures for regenerative medicine	$4M	Werth Ventures, HHS	54/100
2nd	Biogelx 2012, Lanark (United Kingdom), Seed	Supplies peptide hydrogels for cell culture	$983K	Scottish Enterprise, University of Strathclyde ... & 12 others	41/100
3rd	Gel Coat Biomaterials 2024, Chiyoda City (Japan), Seed	Developer of hydrogel technology related to biomaterials and medical applications	$1.33M	WUV	25/100
4th	Sumatrix Biotech 2021, Istanbul (Turkey), Unfunded	Manufacturer of hydrogel materials	-	-	25/100
5th	Matrix Bio 2023, Babraham (United Kingdom), Unfunded	Developer of hydrogel design platform for 3D cell culture applications	-	-	24/100
6th	SPES Tech 2019, Hong Kong (China), Unfunded	Develops recombinant protein hydrogel technology for cell culture	-	-	24/100
7th	Noviocell 2015, Oss (Netherlands), Funding Raised	Developer of 3D cell culture technology for life science research	-	Europa	22/100
8th	PepGel 2012, Manhattan (United States), Funding Raised	Cell culture solutions and innovative biomaterials for regenerative medicine research	-	National Science Foundation	14/100